๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lanzhou
Clinical trial register · China

Clinical Trials in Lanzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.30 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.10 LanZhou University8 Sun Yat-sen University8 Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.7
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Lanzhou

261 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06949033Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
Zuoyi Jiao
Phase 3
668
Lanzhou
2025-05-15
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Maโ€™anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06925243Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
Zuoyi Jiao
Phase 3
682
Lanzhou
2025-04-15
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983Hemophilia A
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784Asthma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
NCT06798207Gynecological Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions
NCT06822712Coronary Arterial Disease (CAD)
BrosMed Medical Co., Ltd
Not applicable
250
Lanzhou
2025-03-03
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Not yet open
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
NCT06861426Acute Ischemic Stroke
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Not yet open
A Clinical Study Comparing Semaglutide Injection and Wegovyยฎ for Weight Management in Obese Subjects
NCT06738979Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
408
Hefei, Xuancheng, Chongqing, Fuzhou, Lanzhou, Guilin, Liuzhou, Nanning
2025-03
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Modified Tumor-free Techniques Operation to Cervical Cancer
NCT06836869Cervical Cancer Stage IB2
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Recruiting
Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus
NCT06821399Diabetes, Diabetic Retinopathy, Type 2 Diabetes Mellitus (T2DM)
Yufan Wang
Observational
2,920
Lanzhou, Shanghai, Shenyang
2025-02-01
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039Diffuse Large B-Cell Lymphoma
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
NCT06737913Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Not yet open
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461Hepatocellular Carcinoma Non-Resectable
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Not yet open
Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study
NCT06794801ST Segment Elevation Myocardial Infarction (STEMI)
LanZhou University
Not applicable
134
Lanzhou
2025-01
Active, closed
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883Chronic Obstructive Pulmonary Disease
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
258
Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen
2024-12-31
Recruiting
A Strategy for Gallstone Expulsion Through Dietary Therapy
NCT06699030Gallbladder Stone
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
100
Lanzhou
2024-12-24
Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
NCT07251309Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Luoyang, Changsha, Chifeng
2024-12-19
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06767800Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169Graft-versus-host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Active, closed
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862Chronic Myelomonocytic Leukemia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
NCT06566586B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Active, closed
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentisยฎ in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Not yet open
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
NCT06469879Small Cell Lung Cancer Limited Stage
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
358
Hefei, Lanzhou, Nanjing, Tangshan, Harbin, Anyang, Xiangyang, Changsha
2024-09
Active, closed
SAVE-PCI: NyokAssistโ„ข Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150Vasodilatory Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
Vor Biopharma
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Active, closed
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT06452537Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
By invitation
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
NCT06782958Amyotrophic Lateral Sclerosis (ALS)
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1
72
Lanzhou
2024-07-05
Active, closed
Health Behavior Nudge Strategies for Chronic Disease Patients: the Study of Hypertension and Type 2 Diabetes
NCT06588127Economics, Behavioral, Hypertension, Type 2 Diabetes Mellitus (T2DM), Self-management Behavior
Lin Han
Not applicable
133
Lanzhou
2024-07-01
Not yet open
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Recruiting
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
NCT05224960Decompensated Cirrhosis
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
NCT06708156Myopia, Myopia Progression
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase 3
606
Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing
2024-06-15
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Not yet open
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
NCT06452693Hepatitis B, Chronic
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
162
Bengbu, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang, Harbin, Shiyan
2024-06
Recruiting
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162Peripheral T-cell Lymphoma
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
By invitation
Effects of Unilateral, Bilateral and Combined Resistance Training on the Speed and Accuracy of the Serve in Youth Tennis Players
NCT06419452Exercise Training
Universiti Putra Malaysia
Not applicable
56
Lanzhou
2024-05-10
Recruiting
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
NCT06300320Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
65
Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai
2024-05-07
Recruiting
Single-operator Versus Two-operator Technique in Single-balloon Enteroscopy
NCT06280469Single-balloon Enteroscopy, Operation
Shuhui Liang
Not applicable
228
Lanzhou, Zhuhai, Xi'an
2024-05-01
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Recruiting
Linking Diet, Inflammation, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study
NCT07211321Sarcopenia
Jianhua Ma
Observational
1,220
Lanzhou
2024-04-16
Recruiting
Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)
NCT07488949Chronic Endometritis
Fang Wang
Not applicable
1,000
Lanzhou
2024-04-09
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT06314906Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
Feixue Song
Phase 3
370
Lanzhou
2024-03-07
Active, closed
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
NCT07687277Glioma, Brain Neoplasms
Lanzhou University Second Hospital
Observational
75
Lanzhou
2024-03-01
By invitation
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
NCT06169579Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wuโ€™an
2024-02-04
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DualityBio Inc.
Phase 3
541
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Huizhou
2024-01-18
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Recruiting
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
NCT06194968Acute Ischemic Stroke
The First Affiliated Hospital of Zhengzhou University
Observational
1,800
Lanzhou, Zhanjiang, Beiliu, Guidong, Wuzhou, Yulin, Sanya, Jiamusi
2023-12-30
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
NCT06155084Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Active, closed
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637Neurofibroma, Plexiform
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Not yet open
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127Locally Advanced or Metastatic NSCLC
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-10-26
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Recruiting
Comparison of a Single Versus Double Perclose Technique for TAVR
NCT06173115Severe Aortic Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
876
Bengbu, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Yulin, Changshacun, Zhengzhou
2023-10-20
Active, closed
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
NCT05987358Biliary Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Recruiting
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
NCT06000956Ankylosing Spondylitis
Tasly Pharmaceutical Group Co., Ltd
Phase 3
408
Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin
2023-09-11
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402Primary Biliary Cholangitis
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yanโ€™an, Kunming, Beijing
2023-08-21
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Recruiting
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500Medullary Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897Crohn's Disease
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Rows per page Showing 101–200 of 261
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/lanzhou?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 261 of those studies with a site in Lanzhou.

How many clinical trials are recruiting in Lanzhou?

147 of the 261 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 50 have not yet opened recruitment, 57 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.